Company intelligence / Profile preview

ImmunoScape

Singapore, Singaporeimmunoscape.com ↗
Ownership
Private
Employees
~50
Development stage
Preclinical
01

Overview

ImmunoScape has not yet entered clinical trials but has developed a robust preclinical pipeline of novel TCR-based therapeutics targeting solid tumors. The company’s technology enables rapid identification of safe and efficacious TCRs with potential for multiple therapeutic modalities. No published clinical results as of May 2025.

Therapeutic areas
OncologyInfectious Diseases
Modalities
TCR-T cell therapies (T cell receptor-based therapeutics)Bispecific immune cell engagersImmune profiling services
Industry
Biotech
02

Drug pipeline

4 assets

IS-002

Preclinical

3 more assets in the full pipeline.

Request access →
03

Partnerships

Experimental Drug Development Centre (EDDC), Singapore/A*STAR – joint development of off-the-shelf bispecific molecules targeting solid tumorsMiNK Therapeutics – collaboration to accelerate novel TCR identification for use in iNKT cells and bispecific engagers against solid tumorsAcademic collaborations with University of Tokyo Edge Capital Partners/UTEC

Beyond the preview

Go deeper on ImmunoScape.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunoScape.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call